Reported Saturday, Cullinan Therapeutics Reports Updated Results From Module C Of Zipalertinib In Phase 2b NSCLC Study At ESMO 2024
Portfolio Pulse from Benzinga Newsdesk
Cullinan Therapeutics reported updated results from its Phase 2b study of zipalertinib for non-small cell lung cancer at ESMO 2024. The study showed a 40% objective response rate and a manageable safety profile in patients with specific mutations. Enrollment for the trial was completed ahead of schedule.
September 16, 2024 | 8:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cullinan Therapeutics' Phase 2b study of zipalertinib shows a 40% response rate in NSCLC patients with specific mutations, indicating potential efficacy and safety. Enrollment completed ahead of schedule, suggesting strong interest and potential future success.
The updated results from the Phase 2b study show a promising 40% response rate and manageable safety profile, which are positive indicators for the drug's potential success. The early completion of enrollment suggests strong interest and confidence in the treatment, likely boosting investor sentiment and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100